Table 4.
Incidence and risk of individual solid cancer subtypes
| sDMARD | TNFi | ETA | INF | ADA | |
|---|---|---|---|---|---|
| N=3249 | N=11 767 | N=4073 | N=3457 | N=4327 | |
| Lung cancer | |||||
| Number | 40 | 103 | 49 | 25 | 29 |
| Incidence rate per 10 000 patient-years (95% CI) | 34 (24 to 47) | 20 (16 to 24) | 22 (16 to 29) | 20 (13 to 30) | 16 (11 to 23) |
| Unadjusted HR (95% CI) | Referent | 0.57 (0.40 to 0.82) | 0.64 (0.42 to 0.98) | 0.59 (0.36 to 0.97) | 0.49 (0.29 to 0.76) |
| Age and sex adjusted HR (95% CI) | Referent | 0.81 (0.56 to 1.17) | 0.95 (0.62 to 1.46) | 0.81 (0.49 to 1.35) | 0.64 (0.40 to 1.04) |
| PD-adjusted HR (95% CI) | Referent | 0.85 (0.52 to 1.39) | 1.02 (0.58 to 1.76) | 0.92 (0.50 to 1.71) | 0.69 (0.39 to 1.23) |
| Female breast cancer | |||||
| Number | 22 | 73 | 30 | 18 | 25 |
| Incidence rate per 10 000 patient-years (95% CI) | 34 (20 to 48) | 18 (14 to 22) | 17 (11 to 23) | 19 (10 to 28) | 17 (10 to 23) |
| Unadjusted HR (95% CI) | Referent | 0.72 (0.45 to 1.17) | 0.70 (0.40 to 1.22) | 0.76 (0.41 to 1.42) | 0.74 (0.42 to 1.31) |
| Age adjusted HR (95% CI) | Referent | 0.83 (0.51 to 1.35) | 0.83 (0.47 to 1.45) | 0.86 (0.46 to 1.61) | 0.83 (0.47 to 1.48) |
| PD-adjusted HR (95% CI) | Referent | 0.58 (0.32 to 1.06) | 0.56 (0.28 to 1.10) | 0.59 (0.28 to 1.24) | 0.59 (0.31 to 1.15) |
| Colorectal cancer | |||||
| Number | 19 | 43 | 16 | 10 | 17 |
| Incidence rate per 10 000 patient-years (95% CI) | 16 (9 to 25) | 8 (6 to 11) | 7 (4 to 12) | 8 (4 to 15) | 9 (5 to 15) |
| Unadjusted HR (95% CI) | Referent | 0.52 (0.30 to 0.89) | 0.46 (0.24 to 0.90) | 0.50 (0.23 to 1.07) | 0.59 (0.31 to 1.14) |
| Age and sex adjusted HR (95% CI) | Referent | 0.71 (0.41 to 1.23) | 0.66 (0.33 to 1.29) | 0.67 (0.31 to 1.44) | 0.79 (0.41 to 1.52) |
| PD-adjusted HR (95% CI) | Referent | 0.51 (0.24 to 1.06) | 0.45 (0.19 to 1.05) | 0.47 (0.19 to 1.20) | 0.57 (0.26 to 1.27) |
| Gastro-oesophageal cancer | |||||
| Number | 12 | 20 | 8 | 5 | 7 |
| Incidence rate per 10 000 patient-years (95% CI) | 10 (5 to 18) | 4 (2 to 6) | 4 (2 to 7) | 4 (1 to 9) | 4 (2 to 8) |
| Unadjusted HR (95% CI) | Referent | 0.35 (0.17 to 0.73) | NR | NR | NR |
| Age and sex adjusted HR (95% CI) | Referent | 0.51 (0.24 to 1.05) | NR | NR | NR |
| PD-adjusted HR (95% CI) | Referent | 0.59 (0.23 to 1.52) | NR | NR | NR |
NR, not reported (indicates fewer than 10 events in each cohort so comparative analyses were not performed).
ADA, adalimumab; ETA, etanercept; INF, infliximab; PD, propensity score stratified into deciles; sDMARD, synthetic disease modifying antirheumatic drug; TNFi, tumour necrosis factor inhibitors.